NEW YORK (GenomeWeb News) - Nanogen yesterday said third-quarter revenues rose 11 percent as R&D spending rose 16 percent and the company cut its net loss by 36 percent.
 
Total receipts for the three months ended Sept. 30 rose to $8.4 million from $7.5 million year over year.
 
The company said product-related revenue increased 17 percent to $5.5 million from $4.7 million, and income from licensing and royalties slipped 2 percent to $1.8 million from $1.9 million.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.